# Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission

> **NCT05502250** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Stichting Hemato-Oncologie voor Volwassenen Nederland** · enrollment: 75 (estimated)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** gemcitabine, cisplatin and tislelizumab

## Key facts

- **NCT ID:** NCT05502250
- **Lead sponsor:** Stichting Hemato-Oncologie voor Volwassenen Nederland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-14
- **Primary completion:** 2028-03
- **Final completion:** 2031-03
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05502250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05502250, "Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05502250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*